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Background: Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be
distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was
to evaluate differences in clinical features and outcome between these two subgroups.
Methods: Outcome and clinical-pathological parameters between 50 patients with NULMS and 45 patients with ULMS
were assessed, and compared between both groups. Univariate and multivariable survival analyses were performed.
Results: Patients with ULMS presented with larger tumors when compared to patients with NULMS (p < 0.001). More
patients with ULMS initially presented with metastatic disease (67% vs. 36%, p = 0.007). Most common metastatic site
was lung for both subtypes (28% and 38%). Five-year overall survival (OS) rates of 82.6% and 41.2% and median OS
times of 92.6 (range: 79.7-105.4) and 50.4 (range: 34.8-66.0) months were observed in patients with NULMS and ULMS,
respectively (p = 0.006). In multivariate analysis, initial metastatic disease remained an independent prognostic factor in
terms of OS (p < 0.0001).
Conclusion: At time of diagnosis ULMS were larger and more often metastasized. Therefore patients with ULMS
showed unfavorable outcome when compared to NULMS. Later diagnosis might be caused by differences in
symptoms and clinical presentation or a more aggressive biological tumor behavior.
Keywords: Outcome, NULMS, ULMS, Prognostic factorsBackground
Leiomyosarcomas (LMS) are a rare large subgroup of all
soft tissue sarcomas (STS) that account for approxi-
mately 24% of all STS. LMS is a mesenchymal tumor of
smooth muscle origin found in the uterus and in soft tis-
sue [1]. LMS can occur anywhere in the body, but the
most frequently affected organs are the retroperitoneal
space, the extremities (NULMS) and the uterus (ULMS).
ULMS is the most common uterine sarcoma and ac-
counts for 40% of all uterine sarcomas [2]. In contrast to
epithelial endometrial cancer, overall prognosis is still
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unless otherwise stated.Management of initially localized NULMS consists of
complete surgical resection and radiation therapy with
overall survival of approximately 8-13 months [4]. Dif-
ferent chemotherapy regimens in the front line as well
in the palliative setting showed promising efficacy in first
line as well in advanced disease [5-7]. Total hysterec-
tomy and bilateral salpingo-oophorectomy is the initial
treatment for women with ULMS. The role of pelvic
lymphadenectomy is unclear and is recommended when
intraoperatively palpable lymph nodes are present or in
women with extrauterine disease. For women with dis-
ease that has spread beyond the uterus but is confined
to the peritoneal cavity surgical cytoreduction is recom-
mended. In patients with metastatic disease that cannot
be completely surgically resected administration of
chemotherapy is favored over adjuvant radiation therapy
RT. Radiation therapy does not show any benefit in earlyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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advanced disease has shown promising results [10-12].
So far the outcome between patients with NULMS
and ULMS seems to be different, but high quality data is
limited. In the largest study so far Oosten et al. reported
outcomes of first line chemotherapy in patients with ad-
vanced or metastatic NULMS and ULMS [13]. Interest-
ingly, no significant differences in outcomes for uterine
and non-uterine LMS were reported in their report.
Thus, the aim of this retrospective study was to evalu-




In total, 50 (53%) patients with NULMS (superficial
LMS were excluded) and 45 (47%) patients with ULMS
were included in this retrospective multicenter study
(Department of Gynecology and Gynecologic Oncology,
Medical University of Vienna, Vienna, Austria: n = 16;
Department of Oncology, Medical University of Vienna,
Vienna, Austria: n = 79) between 1998 and 2013. Data
were collected by chart review. For NULMS, tumor
grading was based on the French Federation of Cancer
Centers Sarcoma Group (FNCLCC) grading system, a
three-grade classification published by Coindre [14]. The
International Federation of Gynecology and Obstetrics
(FIGO) developed a new classification system especially
for ULMS to include different variables like tumor size,
extra uterine spread and invasion of abdominal tissues
[13]. Primary tumor assessment was done using mag-
netic resonance imagining (MRI) and/or computed tom-
ography (CT) and clinical examination. Screening for
distant metastasis was done using CT scans of the chest
and abdomen. Follow up care with CT scans of the chest
and abdomen and MRI of the primary located tumor
was done every three to four months for the first three
years, every six months up to the year five and annually
thereafter. All patients consented to treatment according
to institutional guidelines, and all patients had consented
to anonymized assessments and analysis of data and out-
come of therapy.
Treatment
Treatment consisted of surgical resection of primary
tumor (NULMS: surgical resection of primary disease, in
case of incomplete resection margins, re-resection
within 1 month was performed; ULMS: including hyster-
ectomy, bilateral salpingo-oophorectomy, pelvic and/or
paraaortic lymphadenectomy in presence of intraopera-
tively palpable lymph nodes and surgical cytoreduction
in women with extrauterine disease). If clinically indi-
cated, radiation therapy, adjuvant as well as palliative
chemotherapy was recommended. Radiation therapy wasperformed as 3D CT based conformal therapy. Adjuvant
as well as palliative chemotherapy regimens was used ac-
cording to local practice.
All patients consented to treatment according to insti-
tutional guidelines, and all patients had consented to
anonymized assessments and analysis of data regarding
outcome of therapy. The local ethical committee of the
Medical University of Vienna approved all analyses.
Statistical analysis
For statistical analysis, we used Statistical Package for
the Social Sciences (SPSS) software (SPSS 21.0; SPSS
Inc., Chicago, Illinois). Clinico-pathological parameters
were compared between NULMS and ULMS using Stu-
dents’ t-test, chi-square tests, and One-way ANOVA
analyses where appropriate. Overall survival (OS) was
calculated from the data of primary diagnosis until death
or last follow-up. OS was presented by using Kaplan-
Meier curves and differences between NULMS and
ULMS patients were compared by log-rank test. Univari-
ate survival analyses were performed, compromising pa-
tients’ mean age (≤56.6 vs. >56.6 years), gender (male vs.
female), histologic grade (G1 vs. G2 + 3), Tumor size
(≤5 cm vs. 5-10 cm vs. >10.0 cm), P-values <0.05 were
considered statistically significant. All parameters showing
a significant (p < 0.05) prognostic effect were included into
a multivariable Cox-regression analysis. An event was
defined as death. Radiologic response to adjuvant chemo-
therapy was assessed according to RECIST criteria:
complete response (CR) – no measurable disease; partial
response (PR) - greater than 50% response; stable disease
(SD) – less than 25% response or no response and pro-
gressive disease (PD) [15]. Overall response rate (ORR)
was defined as the proportion of patients whose best over-
all response was either CR or PR.
Results
Baseline characteristics for all patients
Baseline characteristics of patients with NULMS and
ULMS are outlined in Table 1. Fifty patients (female:
n = 22; male: n = 28) presented with NULMS and 45 fe-
male patients presented with ULMS. For patients with
NULMS, most common tumor site was the extremity
(60%) followed by the abdomen (32%). Fifteen patients
with ULMS (33%) presented with FIGO stage I, 3 patients
(7%) with FIGO stage III and 27 patients (60%) with FIGO
stage IV. Twenty-three patients (46%) had a tumor size
≤5 cm and 37 patients (74%) had a deep tumor location.
Nineteen patients (42%) had a tumor size greater than
10.0 cm. Thus, at the time of diagnosis patients with
ULMS had greater tumor size when compared to NULMS
(>10.0 cm: 42% ULMS vs. 10% NULMS, p < 0.001). More
patients with ULMS presented with initial metastatic dis-
ease (67% vs. 36%, p = 0.007). Most common metastatic
Table 1 Baseline characteristics
NULMS ULMS p value
n (%) or median (range) n (%) or median (range)
N 50 (100%) 45 (100%)
Age at first diagnosis 61 (31-88) 54 (32-69) 0.002
Gender <0.001
- Male 28 (56%)
- Female 22 (44%) 45 (100%)
Tumor stage
- FIGO I 15 (33%)
- FIGO III 3 (7%)
- FIGO IV 27 (60%)
Histological grade n = 47 n = 34 0.027
- G 1 1 (2%) 3 (9%)
- G 2 + 3 46 (98%) 31 (91%)
Tumor site n = 50
- Extremities 30 (60%)
- Abdominal 16 (32%)
- Head/neck 2 (4%)
- Thorax 2 (4%)
Tumor size n = 50 n = 45 <0.001
cm 11.1 (3-40) 6.7 (3-14)
- ≤5 cm 23 (46%) 6 (13%)
- 5-10 cm 22 (44%) 14 (32%)
- > 10.0 cm 5 (10%) 19 (42%)
- Not evaluable 6 (13%)
Tumor location n = 50
- Deep/superficial 37 (74%)/13 (26%)
Initial metastatic disease 0.007
- Yes 18 (36%) 30 (67%)
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Table 1 Baseline characteristics (Continued)
Metastatic sites n = 18 n = 30
- Lung 14 (28%) 17 (38%)
- Liver 7 (14%) 5 (11%)
- Bone 4 (8%) 4 (9%)
- Lymph nodes 3 (6%) 8 (18%)
- Other 5 (10%) 15 (33%)
Surgical resection 0.2
- Yes 47 (94%) 45 (100%)
Resection margins n = 47 n = 45 0.048
- Wide 45 (96%) 37 (82%)
- Marginal 2 (4%) 8 (18%)
Re-resection
- Yes 16 (34%)
Pulmonary metastaseectomy 0.6
- Yes 6 (12%) 8 (18%)
Radiationtherapy 0.04
- Yes 29 (58%) 16 (36%)
Adjuvant Chemotherapy for initially
localized disease
- Yes 13 (41%) 8 (53%)
Chemotherapy Regimen for initially
localized disease
- Epirubicine/ifosfamide 6 (46%) 3 (37%)
- Doxorubicine 5 (39%) 1 (13%)
- IFADIC 2 (15%) 2 (25%)
- Gemcitabine/docetaxel 0 2 (25%)
Relapse
- No 12 (92%) 6 (75%)
- Yes 1 (8%) 2 (25%)
First line chemotherapy for initially
metastastic disease
- Yes 18 (36%) 27 (60%)
First line chemotherapy regimen for
initially metastastic disease
n = 18 n = 27
- Doxorubicine 9 (50%) 7 (27%)
- Epirubicine/ifosfamide 6 (33%) 2 (7%)
- IFADIC 0 3 (11%)
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- Other 3 (17%) 2 (7%)
- Gemcitabine/docetaxel 13 (48%)
Response to first line Chemotherapy
for initially metastastic disease
n = 18 n = 27
- Complete remission 4 (22%) 2 (7%)
- Partial remission 2 (11%) 3 (11%)
- Stable disease 4 (22%) 4 (15%)
- Progressive disease 7 (39%) 18 (67%)
- Not evaluable 1 (6%)
Follow-up time (months) 50 (1.2-153.7) 33 (1.5-269.1)
Disease status
Alive/dead 38 (76%)/12 (24%) 20 (44%)/25 (56%)
*Patients had initially localized disease; NULMS = non-uterine leiomyosarcoma; ULMS = uterine leiomyosarcoma.
IFADIC = ifosfamide-doxorubicin-dacarbazine.
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NULMS and pelvic/paraaortic lymph nodes (18%) in
ULMS. Patients with NULMS and ULMS with initially
metastatic disease receiving chemotherapy showed overall
response rates of 33% and 18% and clinical benefit rates of
55% and 33%, respectively.
Patients’ characteristics with NULMS
Baseline characteristics are outlined in Table 1. Thirty-
two patients (64%) presented with initial localized dis-
ease and 13 patients (41%) out of these 32 patients
received chemotherapy. Eighteen patients (36%) pre-
sented with initial metastatic disease. Most common
metastatic sites were lung (28%), followed by liver (14%).
Surgery resection of primary disease was performed in
47 patients (94%). Repeat resection, due to marginal re-
section margins within 1 month after primary tumor re-
section was necessary in 16 patients (34%). Pulmonary
metastasectomy was performed in 6 patients (12%). Pal-
liative radiation therapy and chemotherapy for initial
metastatic disease was performed in 29 (58%) and 18
(36%) patients, respectively. Most common first line pal-
liative chemotherapy regimen for initial metastatic dis-
ease in these 18 patients was doxorubicin (50%). Seven
patients (39%) relapsed after first therapy necessitating
further palliative therapy. Twelve out of 50 patients (24%)
died. Median follow up of all patients was 50 months
(range: 1.2-153.7).
Patients’ characteristics with ULMS
Baseline characteristics are described in Table 1. Fifteen
patients (33%) presented with initial localized diseaseand 30 patients (67%) presented with initial metastatic
disease. Most metastatic sites were pulmonary (38%)
followed by lymph nodes (18%) and liver (11%). All pa-
tients underwent surgical resection of primary disease
with wide resection margins (surgical plane is in normal
tissue) in 37 patients (82%). Pulmonary metastasectomy
was performed in 8 patients (18%). Sixteen patients (36%)
underwent radiation therapy. Palliative chemotherapy for
initial metastatic disease was performed in 27 patients
(60%). Most common palliative first line chemotherapy
regimen of these 27 patients was gemcitabine/docetaxel
(48%). The ORR after first line palliative chemotherapy
was 18%. Twenty-five out of 45 patients died with a me-
dian follow up time of 33 months (range: 1.5-269.1).
Survival
Median OS for patients with NULMS and ULMS was
92.6 (79.7-105.4 95% CI) and 50.4 (34.8-66.0 95% CI)
months, respectively (p = 0.006) (Figure 1). Patients with
initial metastatic disease showed unfavorable outcome
when compared to patients with initial localized disease
as shown in Table 2 and Figure 2 (p < 0.001). Therefore,
these parameters were included into a multivariate
model. In this model, initial metastatic disease remained
an independent prognostic factor (p < 0.001, 95% CI: 3.8-
26.5), whereas tumor location (NULMS vs ULMS) did
not show any prognostic effect (p = 0.1, 95% CI: 0.3-1.1).
A subgroup analysis between initial metastatic NULMS
und ULMS showed no significant difference in OS, but a
trend towards worse outcome for ULMS could be ob-
served (NULMS: 5-yr OS rate: 44.4%; ULMS: 5-yr OS
rate: 16.9%; p = 0.22) (Figure 3).
Figure 1 Overall survival for patients with NULMS (green curve) vs. ULMS (blue curve) (p = 0.006); 5 yr OSR 82.6% (NULMS) vs. 41.2% (ULMS).
Table 2 Univariate survival analyses with 5-year overall
survival rates























5-yr OSR = 5-year Overall survival rate; NULMS = non-uterine LMS.
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be prognostic parameters for overall survival, as outlined
in Table 2. In order to investigate the effect of age on
prognosis of patients with ULMS a subgroup was per-
formed. Results showed that younger women had im-
paired prognosis, just as in the complete cohort of
patients (p = 0.048). A subgroup analysis was performed in
all patients with NULMS in order to investigate a potential
prognostic effect of gender as previously described [16].
There was no survival-difference observed according to
gender (p = 0.96) (Figures 4, 5 and 6).
Discussion
In this retrospective analysis comparing the clinical out-
come of patients with NULMS and ULMS, we found
significant differences in terms of clinical-pathological
parameters and OS between these two groups. Patients
with ULMS were found to have larger tumors and initial
metastatic disease was more frequently observed at time
of diagnosis. In multivariate analysis, initial metastatic
disease was associated with worse OS for patients with
ULMS and therefore seems to be the main cause for the
unfavorable prognosis of patients with ULMS.
At time of diagnosis patients with NULMS presented
with smaller tumors when compared to ULMS. This is
not surprising as NULMS located at the extremities typ-
ically cause early symptoms such as swelling. In contrast
ULMS and abdominal LMS cause unspecific abdominal
symptoms and are frequently incidental findings at time
of hysterectomy or myomectomy [17]. More advanced
disease was also reflected by a higher rate of metastatic
disease in ULMS. Interestingly, the rate of metastatic
disease was high in our study cohort. This finding might
Figure 2 Overall survival for patients with localized (blue line) vs. initially metastasized (green line) NULMS and ULMS (p < 0.001); 5 yr
OSR 91.3% vs. 29.6%.
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center for sarcoma patients and more patients presented
at our department with advanced disease. Interestingly,
patients in our study with ULMS were younger when
compared to patients with NULMS. This might be at-
tributable to differences in tumor biology.
Another reason for the worse outcome may be the
different gene expression between uterine and other
LMSs, as discussed previously [18]. Tumor tissue of ULMSFigure 3 Subgroup analysis: overall survival between initially metastati
44.4%; ULMS: 16.9%; p = 0.22).expresses different genes than NULMS. These genes are
ESR1, HOXA10, PBX1 and FAT, which are regulators for
urogenital differentiation, development and growth [19].
Another recent published work investigated different gene
expression in primary tumor tissue and metastases of
ULMS. The authors concluded different gene expression
between these two subgroups [20]. NULMS are character-
ized by different gene alterations, complex karyotypes with
numerous gains and losses. Some of these aberrations arec NULMS (green curve) and ULMS (blue curve) (5-yr OS: NULMS:
Figure 4 Impact of gender on overall survival of patients with NULMS (p = 0.96); 5 yr OSR 76.6% (male) (blue curve) vs. 77.9% (female)
(pink curve).
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tion, p16 inactivation, RASSF1A increase risk of tumor re-
lated death [21].
Furthermore, NULMS patients had a longer OS when
compared to ULMS patients (p = 0.006). One explan-
ation might be that ULMS are diagnosed at more ad-
vanced stage, like in our study population. Oosten et al.
investigated for the first time the difference according to
OS in patients with un-resectable or metastatic NULMS
and ULMS. No statistically significant differences inFigure 5 Subgroup analysis: overall survival between initially localize
96.0%; ULMS: 81.3%; p = 0.27).outcomes (p = 0.47) were found. Only 36% of all patients
with ULMS presented with distant metastases, when
compared to our patients (67%). Also Salas and col-
leagues described that patient’s age (≥55a), tumor grade
(G3), wide surgical resection margins, and histological
subtype (angiosarcoma) are factors influencing OS in
different superficial STS patients [22]. In contrast, our
report revealed that younger patients showed impaired
outcome. This might partly be explained by the fact that
women with ULMS were younger than patients withd NULMS (green curve) and ULMS (blue curve) (5-yr OS: NULMS:
Figure 6 Subgroup analysis: overall survival between initially metastatic NULMS (green curve) and ULMS (blue curve) (5-yr OS: NULMS:
44.4%; ULMS: 16.9%; p = 0.22).
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group analysis of the influence of age on OS in women
with ULMS showed that younger women had impaired
prognosis, just as in the complete cohort of patients.
Another reason might be that tumors in younger pa-
tients show more aggressive behavior as described in
other malignancies such as gastric cancer [23].
In this study, patients with ULMS showed impaired
survival when compared to NULMS. As we found a
higher rate of initial metastatic disease in ULMS and un-
favorable outcome for patients with metastases in both
univariate and multivariable survival analysis, uterine
tumor location rather seems to be a confounding vari-
able than an independent prognosticator. Nevertheless,
in a subgroup analysis of patients with metastatic disease
we observed a (non-significant) trend towards impaired
survival in patients with ULMS. The authors are aware
that the lack of statistical significance warrants careful
interpretation and validation in larger cohorts.
Male patients showed improved OS in our study.
Interestingly gender did not influence outcome in pa-
tients with NULMS (Figure 4). Therefore it seems likely
that female gender is a confounder for uterine tumor lo-
cation and that gender-specific aspects such as chemo-
sensitivity play a minor role. Nevertheless, our findings
are in contrast to the results reported in the study by
Oosten et al., where male patients with NULMS showed
impaired outcome when compared to female NULMS
patients [16]. Based on their findings the authors had
previously suggested stratifying future clinical trials ac-
cording to gender. Only OS for female patients with
NULMS seemed to be longer when compared to malepatients and female patients with ULMS. It has to be
mentioned that in this trial the outcome was investigated
after first line chemotherapy [16].
Various chemotherapy regimens in the front line as
well in the palliative setting showed promising effect in
first line as well in advanced disease for patients with
NULMS [5-7] as well as ULMS [10,12]. In our study the
similar adjuvant systemic treatment approaches were
used for both patients with NULMS and ULMS. It has
to be underlined that in our study no standardized
chemotherapy protocol was used and that several lines
of systemic therapy were administered based on physi-
cians choice, as it is typical for data generated from
retrospective analysis. Studies suggest that ULMS show
differences with regard to chemotherapy sensitivity
compared to other STS types [19]. Furthermore, in the
present study OS in our patients with NULMS and
ULMS was longer when compared to the study by
Oosten at al. [16] A potential explanation for our find-
ings might be, that patients treated at our institution fre-
quently received several lines of treatment. Furthermore
additional active drugs, such as trabectedin [7,24] and
pazopanib [25], are approved and available in selected
European institutions. Another reason may be, that our
patients received more treatment lines (up to 4 different
cycles of chemotherapy) during their medical history.
There are some study limitations in our study. On the
one hand, it was a retrospective analysis, thus response
rates due to various chemotherapy lines are limited and
cannot be compared with response rates of other pro-
spective trials. On the other hand, our study population
is heterogeneous which is different to prospective trials.
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NULMS and ULMS showed differences in OS in our
study cohort. Patients with ULMS were found to have
larger tumors and initial metastatic disease was more
frequently observed at time of diagnosis. In multivariate
analysis, initial metastatic disease was associated with
worse OS for patients with ULMS and therefore seems
to be the main cause for the unfavorable prognosis of
patients with ULMS. Future studies investigating the dif-
ferences between ULMS and NULMS are warranted in
order to validate our findings. Due to the differences in
clinical presentation and outcome it seems reasonable
that ULMS should be distinguished from NULMS for
future clinical trials.
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